SCHEMBL20764520

SCHEMBL20764520

CC(C)Oc1c(NC(=O)c2ccc(NC(=O)C(CC(N)=O)NC(=O)c3ccc(NC(=O)c4ccc([N+](=O)[O-])c(OC(C)C)c4O)cc3)cc2)ccc(C(=O)Nc2ccc(C(=O)O)cc2)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EP300 Q09472 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MYC P01106 2/20 0.39
▸ MAX P61244 2/20 0.39
▸ MAPT P10636 7/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CTDSP1 Q9GZU7 1/20 0.36
▸ CD40 P25942 1/20 0.36
▸ CD40LG P29965 1/20 0.36
▸ HCAR3 P49019 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20764518 1.00 EP300 (0.41) EP300HIF1ALMNAMYCMAX
SCHEMBL22076730 0.93 ALDH1A1 (0.44) EP300HIF1ALMNAMAPTKMT2A
SCHEMBL22076729 0.93 ALDH1A1 (0.44) EP300HIF1ALMNAMAPTKMT2A
SCHEMBL20764703 0.93 KMT2A (0.47) EP300HIF1AMAPTKMT2AMEN1
SCHEMBL20764701 0.93 KMT2A (0.47) EP300HIF1AMAPTKMT2AMEN1
SCHEMBL20764457 0.93 KMT2A (0.47) EP300HIF1AMAPTKMT2AMEN1
SCHEMBL20764455 0.93 KMT2A (0.47) EP300HIF1AMAPTKMT2AMEN1
SCHEMBL20764481 0.90 MEN1 (0.44) LMNAKMT2AMEN1NPC1HTT
SCHEMBL22076698 0.90 MMP2 (0.38) EP300KMT2AMEN1NPC1POLB
SCHEMBL22076696 0.90 MMP2 (0.38) EP300KMT2AMEN1NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034648-B2 Cystobactamide derivatives HELMHOLTZ-ZENTRUM FÜR (DE) 2021-06-15 — — US disclosed
EP-3672937-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-07-01 — — EP disclosed
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-06-18 — — US disclosed
CN-110997627-A Novel cystobacter amide derivatives 亥姆霍兹感染研究中心有限公司 2020-04-10 — — CN disclosed
WO-2019038405-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034648-B2 Cystobactamide derivatives CTH, CBS, SLC7A11 EP300 3960/4885HIF1A 1589/4885LMNA 4771/4885
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES CTH, CBS, SLC7A11 EP300 4224/4885HIF1A 1978/4885LMNA 4812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback